Zevra Therapeutics (ZVRA) Receivables (2016 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Receivables came in at $22.1 million in Q1 2026, up 75.14% YoY from $12.6 million in Q1 2025, and down 4.99% on a QoQ basis from $23.3 million in Q4 2025.
Zevra Therapeutics (ZVRA) Receivables (2016 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 11 years of Receivables data on file, last reported at $22.1 million in Q1 2026.
- Quarterly Receivables rose 75.14% year-over-year to $22.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.1 million (up 75.14% YoY) and the FY2025 annual result came in at $23.3 million, up 114.52% from the prior year.
- Receivables slipped to $22.1 million in Q1 2026, from $23.3 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $23.3 million in Q4 2025 to a low of $3.1 million in Q2 2022.
- A 5-year average of $11.9 million and a median of $9.9 million in 2023 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 475.72% in 2022, down 70.64% in 2022.
- Tracing ZVRA's Receivables over 5 years: stood at $9.4 million in 2022, then soared by 97.97% to $18.6 million in 2023, then plunged by 41.82% to $10.8 million in 2024, then soared by 114.52% to $23.3 million in 2025, then dropped by 4.99% to $22.1 million in 2026.
- The last three Receivables figures came in at $22.1 million (Q1 2026), $23.3 million (Q4 2025), and $16.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 22.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.49 Mn |
| Mar 31, 2026 | 22.10 Mn |
| Dec 31, 2025 | 23.26 Mn |
| Sep 30, 2025 | 16.84 Mn |
| Jun 30, 2025 | 18.27 Mn |
| Mar 31, 2025 | 12.62 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | 7.79 Mn |
| Jun 30, 2024 | 8.95 Mn |
| Mar 31, 2024 | 8.31 Mn |
| Dec 31, 2023 | 18.64 Mn |
| Sep 30, 2023 | 9.93 Mn |
| Jun 30, 2023 | 14.03 Mn |
| Mar 31, 2023 | 8.52 Mn |
| Dec 31, 2022 | 9.41 Mn |
| Sep 30, 2022 | 6.98 Mn |
| Jun 30, 2022 | 3.12 Mn |
| Mar 31, 2022 | 3.32 Mn |
| Dec 31, 2021 | 1.64 Mn |
| Sep 30, 2021 | 1.62 Mn |